Antipsychotic agents are the backbone of schizophrenia treatment. In recent years, several antipsychotic agents utilizing novel drug combinations, mechanisms of action, and modes of delivery have been introduced into the treatment paradigm, and additional options are in late stages of development. All these new and emerging options create a greater chance for clinicians to individualize treatment, consequently improving patient medication adherence and outcomes
NPs and PAs who care for patients with schizophrenia
This activity is supported by educational grants from Alkermes, Inc. and Teva Pharmaceuticals.
Leslie Citrome, MD, MPH: speaker/consultant: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent, Cerevel, COMPASS, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, INmune Bio, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, MedavanteProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Praxis, Relmada, Reviva, Sage, Sunovion, Supernus, Takeda, and Teva; ownership interest: Bristol-Myers Squibb, Johnson & Johnson, Lilly, Merck, Pfizer, Reviva (options only).
© 2022 Practicing Clinicians Exchange. All Rights Reserved. PRP4650-CT